Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer The difference in median TTP, overall survival, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results